Thyroid disorders in hepatitis c patients treated or not with α-interferon and ribavirin

Endocrinologist

Volumn 20, Issue 3, 2010, Pages 122-124

  Santos, Sandra Regina Xavier ^a   Ferreira, Marcelo Simão ^a   Borges, Aércio Sebastião ^a   De Melo Costa Pinto, Rogério ^a   Pereira Mendonça Fernandes, Maria Luiza ^a   Jorge, Paulo Tannús ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

interferon; Hepatitis C; Hypothyroidism; Ribavirin; Thyroid

Indexed keywords

ALPHA2A INTERFERON; RIBAVIRIN; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN;

ARTICLE; AUTOIMMUNE THYROIDITIS; BLOOD ANALYSIS; CONTROLLED STUDY; HEPATITIS C; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; PREVALENCE; SCREENING TEST; THYROID DISEASE; TREATMENT DURATION;

EID: 77952409177     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/TEN.0b013e3181dfcb01     Document Type: Article

References (25)

1. Word Health Organization Website. Available at: http://www.who.int/ mediacentre/factsheets/fs164/en/. Accessed January 2009.
2. Seeff LB. Natural history of hepatitis C. Am J Med. 1999;107:105-155.
3. Wong T, Lee SS. Hepatitis C: a review for primary care physicians. CMAJ. 2006;174:649-659.
4. Tran HA, Jones TL, Batey RG. The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination interferonalpha2beta and ribavirin. BMC Endocr Disord. 2005;5:8.
5. Bukl J. The hepatitis C virus. In: Schiff ER, Hoofnagle JH. American Association for the Study of Liver Diseases. Update on Viral Hepatitis: the American Association for the Study of Liver Diseases, Postgraduate Course 2000. Dallas, TX:American Association for the Study of Liver Diseases; 2000:102:-111.
6. Ferreira CT, Silveira TR. Viral Hepatitis: epidemiological and preventive aspects. Rev Bras Epidemiol. 2004;7:473-487.
7. Prummel M, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003;13:547-551.
8. Carella C, Mazziotti G, Amato G, et al. Interferon-alpha-related thyroid disease: pathophysiological, epidemiological and clinical aspects. J Clin Endocrinol Metab. 2004;89:3656-3661.
9. Carella C, Mazziotti G, Morisco F, et al. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does modify the thyroid autoantibody by pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol. 2002;146:743-749.
10. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol. 1995;22:364-369.
11. Betterlle C, Fabris P, Zanchetta R, et al. Autoimmunity against pancreatics islets and other tissues before and after interferon therapy in patients with hepatitis C virus chronic infection. Diabetes Care. 2000;23:1177-1181.
12. Wong V, Fu A X L, George J, et al. Thyrotoxicosis induced by alpha interferon therapy in chronic viral hepatitis. Clin Endocrinol. 2002;56:793-798.
13. Marazuella M, Garcia-Monzont L, González-Fernández B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf). 1996;44:635-642.
14. Mandac JC, Chaudhry S, Sherman KE, et al. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 2006;43:661-672.
15. Fernandez Soto L, Gonzales A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during and after discontinuing interferon therapy. Arch Intern Med. 1998;158:1445-1448.
16. Custro N, Montalto G, Scafidi V, et al. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest. 1997;20:374-380.
17. Baudin E, Marcellin P, Pouteau M, et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis. Clin Endocrinol (Oxf). 1993;39:657-661. (Pubitemid 24010954)
18. Kodama T, Katabami S, Kamijo K, et al. Development of transient thyroid disease and reaction during treatment of chronic hepatitis C with inteferon. J Gastroenterol. 1994;29:289-292.
19. Nagayama Y, Ohta K, Tsuruta M, et al. Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature. Endocr J. 1994;41:567-572.
20. Watanabe U, Hashimoto E, Hisamitsu T, et al. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol. 1994;89:399-403.
21. Paraná R, Cruz M, Santos-Jesus M, et al. Thyroid disease in HCV carriers undergoing antiviral therapy with interferon plus ribaverin. Braz J Infect Dis. 2000;4:284-290.
22. Andrade L J O, Atta AM, Junior AD, et al. Thyroid dysfunction in hepatitis C individuals treated with interferon-alfa and ribavirin-a review. Braz J Infect Dis. 2008;12:144-148.
23. Paraná R, Cruz M, Lyra T, et al. Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. J Viral Hepat. 2000;7:393-395.
24. Nduwayo L, Bacq Y, Valat C, et al. Thyroid function and autoimmunity in 215 patients seropositive for the hepatitis C virus. Ann Endocrinol. 1998;59:9-13.
25. Rocco A, Gargano S, Provenzano A, et al. Incidence of autoimmune thyroiditis in interferon-alpha treated and untreated patients with chronic hepatitis C virus infection. Neuro Endocrinol lett. 2001;22:39-44.